vs
Side-by-side financial comparison of Acadia Healthcare Company, Inc. (ACHC) and Evercore Inc. (EVR). Click either name above to swap in a different company.
Evercore Inc. is the larger business by last-quarter revenue ($1.4B vs $829.0M, roughly 1.7× Acadia Healthcare Company, Inc.). Evercore Inc. runs the higher net margin — 23.0% vs 0.5%, a 22.5% gap on every dollar of revenue. On growth, Evercore Inc. posted the faster year-over-year revenue change (100.3% vs 7.5%). Over the past eight quarters, Evercore Inc.'s revenue compounded faster (42.2% CAGR vs 2.0%).
Acadia Healthcare Company, Inc. is an American provider of for-profit behavioral healthcare services. It operates a network of over 225 facilities across the United States and Puerto Rico.
Evercore Inc., formerly known as Evercore Partners, is a global independent investment banking advisory firm founded in 1995 by Roger Altman, David Offensend, and Austin Beutner. The firm has advised on over $4.7 trillion of merger, acquisition, and restructuring transactions since its founding.
ACHC vs EVR — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $829.0M | $1.4B |
| Net Profit | $4.5M | $322.7M |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | 0.5% | 23.0% |
| Revenue YoY | 7.5% | 100.3% |
| Net Profit YoY | -50.8% | 106.1% |
| EPS (diluted) | $0.05 | $7.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $829.0M | $1.4B | ||
| Q4 25 | $821.5M | $1.3B | ||
| Q3 25 | $851.6M | $1.0B | ||
| Q2 25 | $869.2M | $838.0M | ||
| Q1 25 | $770.5M | $699.0M | ||
| Q4 24 | $774.2M | $979.5M | ||
| Q3 24 | $815.6M | $738.4M | ||
| Q2 24 | $796.0M | $693.4M |
| Q1 26 | $4.5M | $322.7M | ||
| Q4 25 | $-1.2B | $204.0M | ||
| Q3 25 | $36.2M | $144.6M | ||
| Q2 25 | $30.1M | $97.2M | ||
| Q1 25 | $8.4M | $146.2M | ||
| Q4 24 | $32.6M | $140.4M | ||
| Q3 24 | $68.1M | $78.4M | ||
| Q2 24 | $78.5M | $73.8M |
| Q1 26 | — | — | ||
| Q4 25 | -142.4% | 24.2% | ||
| Q3 25 | 4.7% | 20.8% | ||
| Q2 25 | 5.8% | 18.0% | ||
| Q1 25 | 1.7% | 16.0% | ||
| Q4 24 | 4.9% | 21.8% | ||
| Q3 24 | 12.1% | 16.7% | ||
| Q2 24 | 13.4% | 15.9% |
| Q1 26 | 0.5% | 23.0% | ||
| Q4 25 | -143.3% | 15.7% | ||
| Q3 25 | 4.3% | 13.8% | ||
| Q2 25 | 3.5% | 11.6% | ||
| Q1 25 | 1.1% | 20.9% | ||
| Q4 24 | 4.2% | 14.3% | ||
| Q3 24 | 8.4% | 10.6% | ||
| Q2 24 | 9.9% | 10.6% |
| Q1 26 | $0.05 | $7.20 | ||
| Q4 25 | $-12.98 | $4.80 | ||
| Q3 25 | $0.40 | $3.41 | ||
| Q2 25 | $0.33 | $2.36 | ||
| Q1 25 | $0.09 | $3.48 | ||
| Q4 24 | $0.36 | $3.32 | ||
| Q3 24 | $0.74 | $1.86 | ||
| Q2 24 | $0.85 | $1.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $158.5M | — |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $2.0B | — |
| Total Assets | $5.5B | — |
| Debt / EquityLower = less leverage | 1.29× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $158.5M | — | ||
| Q4 25 | $133.2M | $3.0B | ||
| Q3 25 | $118.7M | $2.4B | ||
| Q2 25 | $131.4M | $1.7B | ||
| Q1 25 | $91.2M | $1.4B | ||
| Q4 24 | $76.3M | $2.4B | ||
| Q3 24 | $82.1M | $1.8B | ||
| Q2 24 | $77.2M | $1.7B |
| Q1 26 | $2.5B | — | ||
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.3B | — | ||
| Q2 25 | $2.3B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $1.9B | — | ||
| Q2 24 | $1.8B | — |
| Q1 26 | $2.0B | — | ||
| Q4 25 | $1.9B | $2.0B | ||
| Q3 25 | $3.1B | $1.8B | ||
| Q2 25 | $3.1B | $1.7B | ||
| Q1 25 | $3.0B | $1.5B | ||
| Q4 24 | $3.1B | $1.7B | ||
| Q3 24 | $3.0B | $1.6B | ||
| Q2 24 | $3.0B | $1.5B |
| Q1 26 | $5.5B | — | ||
| Q4 25 | $5.5B | $5.4B | ||
| Q3 25 | $6.4B | $4.4B | ||
| Q2 25 | $6.3B | $3.7B | ||
| Q1 25 | $6.1B | $3.3B | ||
| Q4 24 | $6.0B | $4.2B | ||
| Q3 24 | $5.9B | $3.6B | ||
| Q2 24 | $5.7B | $3.3B |
| Q1 26 | 1.29× | — | ||
| Q4 25 | 1.28× | — | ||
| Q3 25 | 0.74× | — | ||
| Q2 25 | 0.74× | — | ||
| Q1 25 | 0.72× | — | ||
| Q4 24 | 0.64× | — | ||
| Q3 24 | 0.62× | — | ||
| Q2 24 | 0.62× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $61.5M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 13.78× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $61.5M | — | ||
| Q4 25 | $-86.3M | $807.5M | ||
| Q3 25 | $73.2M | $560.9M | ||
| Q2 25 | $133.5M | $437.7M | ||
| Q1 25 | $11.5M | $-549.7M | ||
| Q4 24 | $116.7M | $686.4M | ||
| Q3 24 | $163.1M | $234.5M | ||
| Q2 24 | $171.1M | $348.5M |
| Q1 26 | — | — | ||
| Q4 25 | $-179.5M | $798.6M | ||
| Q3 25 | $-63.0M | $541.5M | ||
| Q2 25 | $-34.2M | $411.7M | ||
| Q1 25 | $-163.2M | $-569.3M | ||
| Q4 24 | $-86.8M | $673.1M | ||
| Q3 24 | $-27.1M | $226.6M | ||
| Q2 24 | $16.9M | $340.7M |
| Q1 26 | — | — | ||
| Q4 25 | -21.8% | 61.6% | ||
| Q3 25 | -7.4% | 51.8% | ||
| Q2 25 | -3.9% | 49.1% | ||
| Q1 25 | -21.2% | -81.4% | ||
| Q4 24 | -11.2% | 68.7% | ||
| Q3 24 | -3.3% | 30.7% | ||
| Q2 24 | 2.1% | 49.1% |
| Q1 26 | — | — | ||
| Q4 25 | 11.3% | 0.7% | ||
| Q3 25 | 16.0% | 1.9% | ||
| Q2 25 | 19.3% | 3.1% | ||
| Q1 25 | 22.7% | 2.8% | ||
| Q4 24 | 26.3% | 1.4% | ||
| Q3 24 | 23.3% | 1.1% | ||
| Q2 24 | 19.4% | 1.1% |
| Q1 26 | 13.78× | — | ||
| Q4 25 | — | 3.96× | ||
| Q3 25 | 2.02× | 3.88× | ||
| Q2 25 | 4.43× | 4.50× | ||
| Q1 25 | 1.37× | -3.76× | ||
| Q4 24 | 3.58× | 4.89× | ||
| Q3 24 | 2.39× | 2.99× | ||
| Q2 24 | 2.18× | 4.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACHC
| Acute Inpatient Psychiatric Facilities | $471.0M | 57% |
| Other | $140.0M | 17% |
| Specialty Treatment Facilities | $128.0M | 15% |
| Residential Treatment Facilities | $90.0M | 11% |
EVR
| Advisory Fees (1) | $1.2B | 89% |
| Commissions and Related Revenue | $62.7M | 4% |
| Underwriting Fees | $55.1M | 4% |
| Asset Management and Administration Fees (2) | $23.7M | 2% |
| Other Revenue, net | $15.4M | 1% |
